{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T10:13:58Z","timestamp":1780481638908,"version":"3.54.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.clgc.2019.12.003","type":"journal-article","created":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T03:25:25Z","timestamp":1576207525000},"page":"e443-e449","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["HER2 Status in Molecular Subtypes of Urothelial Carcinoma of the Renal Pelvis and Ureter"],"prefix":"10.1016","volume":"18","author":[{"given":"Takashi","family":"Yorozu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Iwatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Onuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Yanagisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Miki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Egawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Ikegami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8538-0097","authenticated-orcid":false,"given":"Hiroyuki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2019.12.003_bib1","first-page":"1523","article-title":"Upper tract urothelial neoplasms: incidence and survival during the last 2 decades","volume":"164","author":"Munoz","year":"2000","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2019.12.003_bib2","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/cncr.24135","article-title":"Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration","volume":"115","author":"Margulis","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2019.12.003_bib3","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1097\/00000478-200412000-00001","article-title":"Urothelial carcinoma of the renal pelvis: a clinicopathologic study of 130 cases","volume":"28","author":"Olgac","year":"2004","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clgc.2019.12.003_bib4","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.urology.2010.04.020","article-title":"Troubling outcomes from population-level analysis of surgery for upper tract urothelial carcinoma","volume":"76","author":"Abouassaly","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2019.12.003_bib5","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.urolonc.2010.07.016","article-title":"The role of chemotherapy in the treatment of urothelial cell carcinoma of the upper urinary tract (UUCRPUC)","volume":"31","author":"Audenet","year":"2013","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2019.12.003_bib6","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.12.003_bib7","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1200\/JCO.2017.76.9562","article-title":"Health-related quality-of-life analysis from KEYNOTE-045: a phase III study of pembrolizumab versus chemotherapy for previously treated advanced urothelial cancer","volume":"36","author":"Vaughn","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.12.003_bib8","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2019.12.003_bib9","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12253-012-9564-2","article-title":"HER2 status of gastric carcinoma and corresponding lymph node metastasis","volume":"19","author":"Pagni","year":"2013","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.clgc.2019.12.003_bib10","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00428-004-0986-4","article-title":"Confrontation of immunohistochemistry and fluorescent in situ hybridization for the assessment of HER-2\/neu (c-erbb-2) status in urothelial carcinoma","volume":"444","author":"de Pinieux","year":"2004","journal-title":"Virchows Arch"},{"key":"10.1016\/j.clgc.2019.12.003_bib11","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.eururo.2011.05.035","article-title":"Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours","volume":"60","author":"Fleischmann","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2019.12.003_bib12","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejca.2003.08.027","article-title":"HER2\/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy?","volume":"40","author":"Latif","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2019.12.003_bib13","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1309\/41VLTFX3YPP1HF6F","article-title":"HER2 overexpression and amplification in urothelial carcinoma of the bladder is associated with MYC coamplification in a subset of cases","volume":"130","author":"Hansel","year":"2008","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.clgc.2019.12.003_bib14","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.clgc.2019.12.003_bib15","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ccell.2016.05.004","article-title":"Comprehensive transcriptional analysis of early-stage urothelial carcinoma","volume":"30","author":"Hedegaard","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clgc.2019.12.003_bib16","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00428-017-2064-8","article-title":"In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival","volume":"470","author":"Breyer","year":"2017","journal-title":"Virchows Arch"},{"key":"10.1016\/j.clgc.2019.12.003_bib17","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy","volume":"25","author":"Choi","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clgc.2019.12.003_bib18","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.12.003_bib19","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clgc.2019.12.003_bib20","first-page":"699","article-title":"HER2 protein overexpression and gene amplification in upper urinary tract urothelial carcinoma-an analysis of 171 patients","volume":"7","author":"Sasaki","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.clgc.2019.12.003_bib21","first-page":"2544","article-title":"Human epidermal growth factor receptor 2 expression in urothelial carcinoma of the renal pelvis: correlation with clinicopathologic parameters","volume":"7","author":"Ehsani","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.clgc.2019.12.003_bib22","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/1078-0432.CCR-13-1992","article-title":"A\u00a0high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma","volume":"20","author":"Ross","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2019.12.003_bib23","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.ijrobp.2016.12.018","article-title":"A\u00a0phase 1\/2 trial of a combination of paclitaxel and trastuzumab with daily irradiation or paclitaxel alone with daily irradiation after transurethral surgery for noncystectomy candidates with muscle-invasive bladder cancer (Trial NRG Oncology RTOG 0524)","volume":"97","author":"Michaelson","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clgc.2019.12.003_bib24","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767319303763?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767319303763?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:34:52Z","timestamp":1761564892000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767319303763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S1558767319303763"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2019.12.003","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HER2 Status in Molecular Subtypes of Urothelial Carcinoma of the Renal Pelvis and Ureter","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2019.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}